We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Instem Plc | LSE:INS | London | Ordinary Share | GB00B3TQCK30 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 830.00 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMINS
RNS Number : 9166C
Instem plc
13 February 2020
Instem plc
("Instem" or the "Company")
Exercise of Options, Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that, following the exercise of share options by a member of the senior management team, 50,714 new ordinary shares of 10p each in the Company ("Ordinary Shares") have been issued.
Application will be made to the London Stock Exchange for the admission of the 50,714 new Ordinary Shares to trading on AIM ("New Ordinary Shares"). Admission is expected to take place at 8.00 a.m. on 19 February 2020.
Total voting rights
Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 16,673,792 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 16,673,792.
The figure of 16,673,792 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
For further information, please contact:
Instem plc +44 (0) 1785 825 600 Phil Reason, CEO Nigel Goldsmith, CFO N+1 Singer (Nominated Adviser & Broker) +44 (0) 20 7496 3000 Peter Steel / Alex Bond (Corporate Finance) Rachel Hayes (Corporate Broking) Walbrook Financial PR +44 (0) 20 7933 8000 Nick Rome instem@walbrookpr.com Tom Cooper Nicholas Johnson
About Instem
Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.
Instem solutions are in use by over 500 customers worldwide, including all the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.
Instem products and services now address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform at some stage of their development.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
IOEBGGDDLXBDGGX
(END) Dow Jones Newswires
February 13, 2020 05:40 ET (10:40 GMT)
1 Year Instem Chart |
1 Month Instem Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions